Page 7 - Nat Rev News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from AstraZeneca PLC, Lynparza reduced recurrence risk in breast cancer

What is an Antibody Library? The prevalence of diseases such as cancer and the increased need for immunotherapy is driving the development of technologies that target disease-causing cells and organisms. This has driven the development of what is known as an antibody library. This article will discuss this subject. Image Credit: Sakurra/Shutterstock.com Antibodies and the fight against disease When a pathogen infects a healthy host, the host’s immune system responds to fight it off and maintain health. The host produces antibodies that recognize the antigens present on the surface of the in...

55 which revealed that males have a higher risk of hyperuricemia. The higher likelihood of hyperuricemia in males than females may be due to the action of sex hormones, in that the female sex hormone estrogen helps in the excretion of uric acid and could have the ability to maintain blood uric acid levels. 56,57 Besides, the risk of exposure to environmental and dietary factors that aid the synthesis of purine is higher in males than females, which may also contribute to the production of more uric acid owing to regulatory activity of purine metabolism, which further results in the release of...

Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm) Tonix Pharmaceuticals Holding Corp. Expands Proprietary Uses of Tonix’s Potentiated Oxytocin for Intranasal Administration Disorder Stunts Growth of Newborns and, Paradoxically, Can Cause Excessive Hunger During Childhood and Beyond CHATHAM, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today...

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments - Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million - Angelini Pharma will become a leading player amongst companies focused on Central Nervous System (CNS) and mental health disorder treatments - Opening direct affiliates in France, UK, Nordics and Switzerland by 2022 News provided by Share this article ROME, Jan. 14, 2021 /PRNewswire/ --  Angelin...